. home.aspx

NEWS

home.aspx
   


FDA widens scope of Pfizer’s Sutent in kidney cancer

November 17, 2017 / Selina McKee
SHARESHARESHARE

The US Food and Drug Administration has cleared Pfizer’s Sutent for adjuvant treatment of adults at a high risk of their kidney cancer returning after a kidney has been removed.